Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm

15.10.18 12:00
Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm

Bagsværd, Denmark, 15 October 2018 - Novo Nordisk A/S today announced the appointment of Ludovic Helfgott as executive vice president of Biopharm, effective 3 April 2019.

Based in Zürich, Switzerland, Helfgott will lead the development of Novo Nordisk's Biopharm business, which comprises the company's haemophilia and human growth hormone franchises. He will be a member of Novo Nordisk's Executive Management team and report to CEO Lars Fruergaard Jørgensen.

Ludovic Helfgott joins Novo Nordisk from AstraZeneca where he most recently was global vice president in charge of the company's Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. A French national, Helfgott holds an MBA from Insead.

Commenting on his new role, he says: "I'm excited to join Novo Nordisk and look forward to working with the Biopharm team on improving lives for people with haemophilia, growth disorders and other serious chronic diseases".

Jesper Brandgaard, executive vice president, Biopharm & Legal Affairs, has decided to retire after a distinguished 20-year career at Novo Nordisk. He will remain in charge of Biopharm & Legal Affairs until Ludovic Helfgott assumes the responsibility of Novo Nordisk's Biopharm business.

Lars Fruergaard Jørgensen says: "I am delighted to welcome Ludovic Helfgott to Novo Nordisk and my executive team. He brings with him extensive experience in the development and launch of treatments for people with chronic diseases. In his new role, he will be instrumental in driving the continued development of our Biopharm business. I would also like to thank Jesper Brandgaard for his significant contributions to Novo Nordisk, both as our CFO for many years and most recently as head of Biopharm, where he has taken important steps towards bringing the business back on a growth track. I'm pleased that Jesper will continue in his current role until Ludovic joins Novo Nordisk."

Jesper Brandgaard says: "It has been a privilege for me to be part of Novo Nordisk's journey during my 20 years with the company. With strong successors in place within Finance, Legal Affairs and Biopharm, April 2019 will be a good time for me to pursue a non-executive career."

Further information

Charlotte Zarp-Andersson +45 3079 7603
Ken Inchausti (US) +1 609 240 9429
Peter Hugreffe Ankersen +45 3075 9085
Anders Mikkelsen +45 3079 4461
Valdemar Borum Svarrer +45 3079 0301

Company announcement No 78 / 2018


This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:


Aktuelle Diskussionen zum Thema:

Novo-Nordisk - Insulinpräparate (05.08.20)
Dividenden-Giganten (10.12.16)
Thema Diabetis-Insulien (23.02.15)

Aktuelle Nachrichten zum Unternehmen:

Novo Nordisk: 485 oder 330 DKK. (05.08.20)
Novo Nordisk: Kursziel gesenkt (04.08.20)
Novo Nordisk: Wo wird die Aktie . (29.07.20)
Novo Nordisk & LTC Properties: Id. (18.07.20)
Novo Nordisk: KGV 26, Dividenden. (10.07.20)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Weitere Meldungen
15.10 Ad hoc: Linde AG: Höhe de.
15.10 Ad hoc: GRAMMER AG - .
15.10 Ad hoc: Drägerwerk AG & .
15.10 Ad hoc: Leifheit Aktiengese.
15.10 Ad hoc: SMA Solar Techno.
15.10 Signify share repurchase pe.
15.10 Ad hoc: Beiersdorf Aktienge.
15.10 Novo Nordisk appoints Ludov.
15.10 REC Silicon - Invitation to t.
15.10 Ad hoc: paragon GmbH & C.
15.10 SeaBird Exploration: SeaBird.
15.10 Klövern AB (publ): Klövern .
13.10 Ad hoc: CECONOMY AG: P.
12.10 WISeKey Leverages its Cer.
12.10 Maurel & Prom: confirms it .
12.10 INVENTIVA to Participate i.
12.10 SeaBird Exploration: SeaBird.
12.10 Ad hoc: ad pepper media In.
12.10 Ad hoc: niiio finance group .
12.10 Ad hoc: Sino-German United.
12.10 Ad hoc: UMS United Medica.
12.10 TGS and Schlumberger Ann.
12.10 Incap to increase its estimat.
11.10 Eckert & Ziegler BEBIG SA.
11.10 Ad hoc: cyan AG: Durchfüh.
11.10 Ad hoc: BB Biotech AG rap.
11.10 Virbac : revenue grew by +.
11.10 Ad hoc: HWA AG soll neu.
11.10 Net Insight's Nomination Com.
11.10 Prosafe SE: Safe Zephyrus .

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 66107 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
3 Dinge, die Sie zum erfolgreichen Trading NICHT brauchen
Experte: Stefan Hofmann, STOCK-WORLD
Erdgas - So wertvoll ist ...
Philip Klinkmüller, HKCM (05.08.20)
Experte: Philip Klinkmüller, HKCM
Bitcoin / Ethereum - ...
Philip Hopf, Hopf Klinkmüller Capital. (05.08.20)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
DAX DOW mit der starken ...
Thomas Heydrich, (05.08.20)
Experte: Thomas Heydrich,
Joe Biden - Schock für die ...
Feingold-Research, (05.08.20)
Experte: Feingold-Research,
S&P500 - Nach oben alle ...
Christian Zoller, (05.08.20)
Experte: Christian Zoller,
DAX nach oben gedeckelt -...
CMC Markets, (05.08.20)
Experte: CMC Markets,
Jörg Schulte, JS-Research (05.08.20)
Experte: Jörg Schulte, JS-Research
Dow Jones - Die Bullen ...
HypoVereinsbank onema., (05.08.20)
Experte: HypoVereinsbank onemarkets,
Plug Power, Ballard und ..., (05.08.20)
Euwax-Trends: Daimler ...
Cornelia Frey, Börse Stuttgart AG (05.08.20)
Experte: Cornelia Frey, Börse Stuttgart AG
Des Autokraten Traum
Michael Beck, Leiter Po., Bankhaus ELLWANGER. (05.08.20)
Experte: Michael Beck, Leiter Portfolio M., Bankhaus ELLWANGER & GEIGER K.
Evonik-Calls mit hohen ...
Walter Kozubek, (05.08.20)
Experte: Walter Kozubek,
Niquet's World
Neues vom Portal
Das beste Spielhaus im kommenden Jahr
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen